中国新药杂志

用于非小细胞肺癌治疗的肝细胞生长因子受体抑制剂capmatinib

PDF下载

童颖 ¹ , 黄璐 ²^,³^,⁴ , 熊传爽 ¹ , 洪怡 ¹ , 许勇 ¹

中国新药杂志 | 新药述评与论坛 2021,30(14): 1255-1259

收起

中国新药杂志 |新药述评与论坛 2021 , 30 (14) : 1255 -1259

用于非小细胞肺癌治疗的肝细胞生长因子受体抑制剂capmatinib

全屏

童颖¹, 黄璐²^,³^,⁴, 熊传爽¹, 洪怡¹, 许勇¹

作者信息

¹湖北中医药大学药学院，武汉　430065

²武汉大学药学院，武汉　430072

³武汉工程大学化工与制药学院，武汉　430205

⁴广州丹康医药生物有限公司，广州　510200

通讯作者:

洪怡，女，博士，副教授，硕士生导师，主要从事药物制剂新技术与新药研发工作。E-mail：46447564@qq.com。

许勇，男，博士，教授，主要从事新药开发与医药知识产权工作。E-mail：xuwuhan@hotmail.com。

作者简介:

童颖，女，在读硕士研究生，主要从事药物制剂研究。E-mail：673152506@qq.com。

Hepatocyte growth factor receptor inhibitor capmatinib for the treatment of non-small cell lung cancer

Ying TONG¹, Lu HUANG²^,³^,⁴, Chuan-shuang XIONG¹, Yi HONG¹, Yong XU¹

Affiliations

¹School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China

²School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China

³School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205, China

⁴Guangzhou Wellhealth Bio-pharma Co., Ltd., Guangzhou 510200, China

出版时间: 2021-07-30

文章导航

摘要

收起

capmatinib是一种肝细胞生长因子受体（MET）抑制剂，于2020年5月6日被美国FDA批准上市，用于治疗携带MET14外显子跳跃突变的不可切除的局部晚期或转移性的非小细胞肺癌（NSCLC）成年患者，此次批准意味着继Tepmetko^®上市后治疗MET突变NSCLC患者的又一重大创新。本文对其作用机制、药动学、药效学、临床研究、安全性、知识产权等进行综述。

关键词

capmatinib / 肝细胞生长因子受体抑制剂 / 非小细胞肺癌 / 临床研究 / 安全性 / 知识产权

Abstract

收起

Capmatinib is a hepatocyte growth factor receptor (MET) inhibitor, which was approved by the US FDA on May 6, 2020 for the treatment of adult patients with non-resectable locally advanced or metastatic non-small cell lung cancer with MET14 exon jumping mutation. This approval means another significant innovation in the treatment of NSCLC patients with MET mutation after the listing of Tepmetko^®. In this paper, the mechanism of action, pharmacokinetics, pharmacodynamics, clinical research, safety and intellectual property right of the drug were reviewed.

Key words

capmatinib / hepatocyte growth factor receptor inhibitor / non-small cell lung cancer / clinical research / safety / intellectual property right

引用本文

童颖, 黄璐, 熊传爽, 洪怡, 许勇. 用于非小细胞肺癌治疗的肝细胞生长因子受体抑制剂capmatinib. 中国新药杂志, 2021 , 30 (14) : 1255 -1259 .

Ying TONG, Lu HUANG, Chuan-shuang XIONG, Yi HONG, Yong XU. Hepatocyte growth factor receptor inhibitor capmatinib for the treatment of non-small cell lung cancer[J]. Chinese Journal of New Drugs, 2021 , 30 (14) : 1255 -1259 .

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA-Cancer J Clin, 2018, 68(6): 394-424.

[2]

王春梅, 高艳丽, 尹丽霞. 非小细胞肺癌放射治疗研究进展[J]. 中华肿瘤防治杂志, 2017, 24(10): 720-724.

[3]

张楠, 李琰琰, 顾建华, 等. 肥城市农村居民肺癌发病趋势分析及预测[J]. 中国肿瘤临床, 2018, 45(7): 366370.

[4]

KRIS MG, JOHNSON BE, KWIATKOWSKI DJ, et al. Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMO)[J]. Clin Oncol, 2011, 29(18): CRA7506.

[5]

BROAD I, HAMMERMAN PS, LAWRENCE MS, et al. Comprehensive genomic characterization of squamous cell lung cancers[J]. Nature, 2012, 489(7417): 519-525.

[6]

RUSSO A, LOPES AR, MCCUSKER MG, et al. New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)[J]. Curr Oncol Rep, 2020, 22(5): 1-14.

[7]

KIM NA, HONG S, KIM KH, et al. New preclinical development of a c-Met inhibitor and its combined anti-tumor effect in c-Met-amplified NSCLC[J]. Pharmaceutics, 2020, 12(2): 121.

[8]

JOHNE A, SCHEIBLE H, BECKER A, et al. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers[J]. Invest New Drugs, 2020, 38(5): 1507-1519.

[9]

MARKHAM A. Tepotinib: first approval[J]. Drugs, 2020, 80(8): 829-833.

[10]

BONAN NF, KOWALSKI D, KUDLAC K, et al. Inhibition of HGF/MET signaling decreases overall tumor burden and blocks malignant conversion in Tpl2-related skin cancer[J]. Oncogenesis, 2019, 8(1): 1-12.

[11]

SATTLER M, HASINA R, REDDY MM, et al. The role of the c-Met pathway in lung cancer and the potential for targeted therapy[J]. Ther Adv Med Oncol, 2011, 3(4): 171-184.

[12]

SCHROCK AB, FRAMPTON GM, SUH J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations[J]. Thorac Oncol, 2016, 11(9): 1493-1502.

[13]

BALTSCHUKAT S, ENGSTLER BS, HUANG A, et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation[J]. Clin Cancer Res, 2019, 25(10): 3164-3175.

[14]

ESAKI T, HIRAI F, MAKIYAMA A, et al. Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors[J]. Cancer Sci, 2019, 110(4): 1340.

[15]

Novartis. Prescribing Information for Tabrecta[EB/OL]. (2020-01-22) [2020-05-30]. https://www.rxlist.com/tabrecta-drug.htm#description, June 2020.

[16]

LIU X, WANG Q, YANG G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3[J]. Clin Cancer Res, 2011, 17(22): 7127-7138.

[17]

PAIK PK, VEILLON R, CORTOT AB, et al. Phase II study of tepotinib in NSCLC patients with MET ex14 mutations[J]. J Clin Oncol, 2019, 37(15): Abstract 9005.

[18]

WOLF J, SETO T, HAN JY, et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study[J]. J Clin Oncol, 2019, 37(15): 9004.

[19]

WU YL, ZHANG L, KIM DW, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer[J]. J Clin Oncol, 2018, 36(31): 3101.

[20]

QIN S, CHAN SL, SUKEEPAISARNJAROEN W, et al. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2019, 11: 1-12.

[21]

SCHULER M, BERARDI R, LIM WT, et al. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a Phase I trial[J]. Ann Oncol, 2020, 31(6): 789-797.

[22]

SCHULER MH, BERARDI R, LIM WT, et al. Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2016, 34(15): 9067.

[23]

ESCUDIER B, MOLINIE V, BRACARDA S, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis[J]. Eur J Cancer, 2016, 69: 226-235.

[24]

黄璐, 余浩, 张长春, 等. 药品研发过程中的知识产权制度及运用[J]. 中国新药杂志, 2019, 28(1): 10-16.

2021年第30卷第14期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-07-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-10-20

基金

作者信息

¹湖北中医药大学药学院，武汉　430065

²武汉大学药学院，武汉　430072

³武汉工程大学化工与制药学院，武汉　430205

⁴广州丹康医药生物有限公司，广州　510200

通讯作者:

洪怡，女，博士，副教授，硕士生导师，主要从事药物制剂新技术与新药研发工作。E-mail：46447564@qq.com。

许勇，男，博士，教授，主要从事新药开发与医药知识产权工作。E-mail：xuwuhan@hotmail.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322181119550796604

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT